Unresponsiveness to AmBisome in some Sudanese patients with kala-azar
Authors:
- Koert RitmeijerKRKoert Ritmeijer
- Manica BalasegaramMBManica Balasegaram
- Youssif KoummukiYKYoussif Koummuki
- Muriel Ramirez SantanaMSMuriel Ramirez Santana
- Robert DavidsonRDRobert Davidson
- 1 January 2007
- journal article
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 101 (1) , 19-24
Abstract
In Sudan, two treatments are currently registered for visceral leishmaniasis: sodium stibogluconate (SSG) as first line and liposomal amphotericin B (AmBisome) as second line. We present 64 patients (52 relapse cases to SSG, 12 new but complicated cases) treated with AmBisome in eastern Sudan. AmBisome was administered at 2.5-8.2mg/kg (15-49mg/kg in total) per dose six times (days 1, 2, 3, 5, 10, 15) as an intravenous infusion. We measured outcome according to clinical response and parasitological clearance (lymph node aspiration). Patient outcomes fell into three groups: group 1, clinical responders (cured) with a negative test of cure (n=35); group 2, clinical responders with a positive test of cure (n=19); group 3, clinical non-responders (failures) with a positive test of cure (n=10). Of the 10 failures, six were already relapse cases. All of group 3, and 15 from group 2, were also treated with additional SSG (20mg/kg intramuscularly daily for 30-50 d) with resulting clinical and parasitological improvement. Parasite persistence and clinical failure were associated with a higher parasite density on admission (P<0.002) and underlying immunosuppressive disease: tuberculosis (three cases) or HIV (two cases). Because AmBisome monotherapy may fail in Sudan, a combination of AmBisome and SSG is recommended for relapse cases.Keywords
This publication has 10 references indexed in Scilit:
- Recent developments in Leishmaniasis: Epidemiology, diagnosis, and treatmentCurrent Infectious Disease Reports, 2005
- L’amphotéricine B liposomale en prophylaxie secondaire chez les patients VIH+ atteints de leishmaniose viscérale : à propos de cinq casPathologie Biologie, 2004
- Current treatment approaches to leishmaniasisCurrent Opinion in Infectious Diseases, 2003
- AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experienceJournal of Antimicrobial Chemotherapy, 2002
- In Vitro Reversion of Amphotericin B Resistance in Leishmania donovani by Poloxamer 188Antimicrobial Agents and Chemotherapy, 2000
- Comparison of three treatment regimens with liposomal amphotericin B (AmBisome®) for visceral leishmaniasis in India: a randomized dose-finding studyTransactions of the Royal Society of Tropical Medicine and Hygiene, 1996
- Visceral leishmaniasis in HIV infected patients: Treatment with high dose liposomal amphotericin B (AmBisome)Journal of Infection, 1996
- Liposomal Amphotericin B (AmBisome) in the Treatment of Complicated Kala-Azar Under Field ConditionsClinical Infectious Diseases, 1995
- Relapse of Visceral Leishmaniasis in Patients Who Were Coinfected with Human Immunodeficiency Virus and Who Received Treatment with Liposomal Amphotericin BClinical Infectious Diseases, 1994
- Quantitation of Amastigotes of Leishmania Donovani in Smears of Splenic Aspirates from Patients with Visceral LeishmaniasisThe American Journal of Tropical Medicine and Hygiene, 1983